Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Milestones: House Bill By Memorial Day, Enactment By July 4

Executive Summary

Introduction of a drug benefit bill by Rep. Thomas (R-Calif.) before the Memorial Day recess is a near-term marker to predict the prospects for enactment of a Medicare prescription drug bill in 2000.

You may also be interested in...



Medicare Drug Benefit Unlikely To Pass This Year, Lobbyist Steelman Says

Congress is "very unlikely" to pass a Medicare drug benefit bill this year, Steelman Health Strategies President Deborah Steelman told a healthcare conference sponsored by the Schwab Washington Research Group May 22 in Washington, D.C.

Medicare Drug Benefit Unlikely To Pass This Year, Lobbyist Steelman Says

Congress is "very unlikely" to pass a Medicare drug benefit bill this year, Steelman Health Strategies President Deborah Steelman told a healthcare conference sponsored by the Schwab Washington Research Group May 22 in Washington, D.C.

PBMs Would Be "Full Partners" With Government Under Thomas Medicare Bill

Pharmaceutical benefit management companies will have the opportunity to become part of a "public-private partnership" with the federal government under Rep. Thomas' (R-Calif.) upcoming Medicare prescription drug bill.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036036

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel